The QPS Neuropharmacology department, led by Dr. Birgit Hutter-Paier, specializes in all neurology related pharmaceutical research. With a special focus on Neurodegeneration and Orphan diseases, QPS is dedicated to supporting our clients projects in preclinical phases of drug development. Over the last two decades we have constantly increased our portfolio of in vitro and in vivo models for indications like Alzheimer’s, Parkinson’s, Huntington’s, ALS, Lysosomal Storage Diseases like Gaucher and Niemann-Pick disease, and many more. Based on the vast experience of our team, our role is to guide our clients to set up the best possible study designed to evaluate the efficiency of their NCEs or biologics. Well characterized in vitro (cell cultures, stem cells) and in vivo models (transgenic, non-transgenic, induced animal models), as well as behavioral, biochemical and histological techniques are combined, and the total output of these techniques is vital to the success of your overall study. QPS Neuropharmacology combines it’s proven scientific expertise in the field of Neurodegeneration and Orphan diseases with extensive knowledge resulting from more than 2,000 finished projects and the highest quality standards.
The QPS Neurology department, is led by Dr. Bruce Kohrman, a Board Certified Neurologist, and is focused on all phases of Clinical Trials in Neurodegenerative disorders. Our large study subject databases, in addition to our in-house advertising agencies, enable QPS to consistently land in the top 20% of study subject enrollers nationwide. We use a central IRB to ensure full regulatory compliance and we consistently employ rigorous standard operating procedures. The QPS Quality Assurance department, Regulatory department, and experienced Study Coordinators consistently provide quality results.
Jointly, the Neuropharmacology and Neurology departments of QPS have been conducting top-quality preclinical and clinic pharmaceutical research for over 25 years, published papers in peer-reviewed and nationally recognized journals, and provided safety and efficacy data for a myriad of investigational compounds and other products. QPS spans the full range of drug development services, ensuring that we are a flexible and agile partner in your global drug development program. In addition, our passion for building long-lasting relationships with our clients clearly sets us apart. Across all of QPS, we promote a customer-focused culture that spans our entire array of services.
SPECIALTY AREAS OF FOCUS
Our Neuropharmacology and Neurology Departments specialize in investigating:
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis
- Cerebrovascular Disease
- Chronic Pain
- Epilepsy
- Huntington’s Disease
- Lysosomal Storage Diseases
- Migraine
- Acute Care
- Preventative
- Mild Cognitive Impairment
- Multi-infarct Dementia
- Multiple Sclerosis
- Parkinson’s Disease
- Peripheral Neuropathic Pain
- Psychiatric Diseases
ASSESSMENT CAPABILITIES
On-site Neurology-specific technologies and assessment abilities include:
- Biofeedback
- Electroencephalography
- Electromyography
- Evoked Potentials
- Intraoperative monitoring
- Nerve Conduction
- Neuropsychological testing
- Psychological Testing
- Psychometric Assessment
BIRGIT HUTTER-PAIER, Ph.D.
Birgit Hutter-Paier has been the Head of Neuropharmacology at QPS for more than 20 years. Trained as a pharmacologist with focus on animal behavior, especially learning and memory, Hutter-Paier started her career building a world class research team for a pharmaceutical company. Later she helped start and grow a contract research organization (CRO) with focus on in vitro and in vivo neurodegeneration models. She holds a PhD in zoology and biochemistry from Karl-Franzens-Universität in Graz, Austria.
